Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Market Chatter: Solstice Advanced Materials Pressured by Starboard Value Activist Hedge Fund

Market Chatter: Solstice Advanced Materials Pressured by Starboard Value Activist Hedge Fund

MT newswireMT newswire2026/10/20 08:39
04:39 AM EDT, 10/20/2026 (MT Newswires) -- Solstice Advanced Materials (SOLS) is under pressure from activist hedge fund Starboard Value to cut costs and boost its share price, the Financial Times reported on Tuesday, citing anonymous sources. Starboard wants Solstice to cut $100 million in overhead and focus on its refrigerants and nuclear businesses. The hedge fund anticipates Solstice's nuclear business, which supplies a key chemical used to enrich uranium, could become more valuable pending a 2028 Washington deadline to halt the import of Russian uranium and rising electricity demands due to artificial intelligence. Starboard's founder and CEO Jeff Smith is expected to provide more detail on his Solstice investment on Tuesday, at the 13D Monitor Active-Passive Investor Summit, an annual meeting of activist investors. Representatives from Solstice and Starboard did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12